147 related articles for article (PubMed ID: 21446745)
1. Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors.
Johnson TW; Tanis SP; Butler SL; Dalvie D; Delisle DM; Dress KR; Flahive EJ; Hu Q; Kuehler JE; Kuki A; Liu W; McClellan GA; Peng Q; Plewe MB; Richardson PF; Smith GL; Solowiej J; Tran KT; Wang H; Yu X; Zhang J; Zhu H
J Med Chem; 2011 May; 54(9):3393-417. PubMed ID: 21446745
[TBL] [Abstract][Full Text] [Related]
2. Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors.
Plewe MB; Butler SL; Dress KR; Hu Q; Johnson TW; Kuehler JE; Kuki A; Lam H; Liu W; Nowlin D; Peng Q; Rahavendran SV; Tanis SP; Tran KT; Wang H; Yang A; Zhang J
J Med Chem; 2009 Nov; 52(22):7211-9. PubMed ID: 19873974
[TBL] [Abstract][Full Text] [Related]
3. A potent and orally active HIV-1 integrase inhibitor.
Egbertson MS; Moritz HM; Melamed JY; Han W; Perlow DS; Kuo MS; Embrey M; Vacca JP; Zrada MM; Cortes AR; Wallace A; Leonard Y; Hazuda DJ; Miller MD; Felock PJ; Stillmock KA; Witmer MV; Schleif W; Gabryelski LJ; Moyer G; Ellis JD; Jin L; Xu W; Braun MP; Kassahun K; Tsou NN; Young SD
Bioorg Med Chem Lett; 2007 Mar; 17(5):1392-8. PubMed ID: 17194584
[TBL] [Abstract][Full Text] [Related]
4. Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones.
Gardelli C; Nizi E; Muraglia E; Crescenzi B; Ferrara M; Orvieto F; Pace P; Pescatore G; Poma M; Ferreira Mdel R; Scarpelli R; Homnick CF; Ikemoto N; Alfieri A; Verdirame M; Bonelli F; Paz OG; Taliani M; Monteagudo E; Pesci S; Laufer R; Felock P; Stillmock KA; Hazuda D; Rowley M; Summa V
J Med Chem; 2007 Oct; 50(20):4953-75. PubMed ID: 17824681
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells.
Zhuang L; Wai JS; Embrey MW; Fisher TE; Egbertson MS; Payne LS; Guare JP; Vacca JP; Hazuda DJ; Felock PJ; Wolfe AL; Stillmock KA; Witmer MV; Moyer G; Schleif WA; Gabryelski LJ; Leonard YM; Lynch JJ; Michelson SR; Young SD
J Med Chem; 2003 Feb; 46(4):453-6. PubMed ID: 12570367
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase.
Melamed JY; Egbertson MS; Varga S; Vacca JP; Moyer G; Gabryelski L; Felock PJ; Stillmock KA; Witmer MV; Schleif W; Hazuda DJ; Leonard Y; Jin L; Ellis JD; Young SD
Bioorg Med Chem Lett; 2008 Oct; 18(19):5307-10. PubMed ID: 18774711
[TBL] [Abstract][Full Text] [Related]
7. Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PK.
Tanis SP; Plewe MB; Johnson TW; Butler SL; Dalvie D; DeLisle D; Dress KR; Hu Q; Huang B; Kuehler JE; Kuki A; Liu W; Peng Q; Smith GL; Solowiej J; Tran KT; Wang H; Yang A; Yin C; Yu X; Zhang J; Zhu H
Bioorg Med Chem Lett; 2010 Dec; 20(24):7429-34. PubMed ID: 21036042
[TBL] [Abstract][Full Text] [Related]
8. Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase.
Verschueren WG; Dierynck I; Amssoms KI; Hu L; Boonants PM; Pille GM; Daeyaert FF; Hertogs K; Surleraux DL; Wigerinck PB
J Med Chem; 2005 Mar; 48(6):1930-40. PubMed ID: 15771437
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antiviral activity of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV integrase inhibitors.
Boros EE; Edwards CE; Foster SA; Fuji M; Fujiwara T; Garvey EP; Golden PL; Hazen RJ; Jeffrey JL; Johns BA; Kawasuji T; Kiyama R; Koble CS; Kurose N; Miller WH; Mote AL; Murai H; Sato A; Thompson JB; Woodward MC; Yoshinaga T
J Med Chem; 2009 May; 52(9):2754-61. PubMed ID: 19374386
[TBL] [Abstract][Full Text] [Related]
10. A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.
Embrey MW; Wai JS; Funk TW; Homnick CF; Perlow DS; Young SD; Vacca JP; Hazuda DJ; Felock PJ; Stillmock KA; Witmer MV; Moyer G; Schleif WA; Gabryelski LJ; Jin L; Chen IW; Ellis JD; Wong BK; Lin JH; Leonard YM; Tsou NN; Zhuang L
Bioorg Med Chem Lett; 2005 Oct; 15(20):4550-4. PubMed ID: 16102965
[TBL] [Abstract][Full Text] [Related]
11. Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs.
Jin H; Wright M; Pastor R; Mish M; Metobo S; Jabri S; Lansdown R; Cai R; Pyun P; Tsiang M; Chen X; Kim CU
Bioorg Med Chem Lett; 2008 Feb; 18(4):1388-91. PubMed ID: 18207398
[TBL] [Abstract][Full Text] [Related]
12. Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors.
Pace P; Di Francesco ME; Gardelli C; Harper S; Muraglia E; Nizi E; Orvieto F; Petrocchi A; Poma M; Rowley M; Scarpelli R; Laufer R; Gonzalez Paz O; Monteagudo E; Bonelli F; Hazuda D; Stillmock KA; Summa V
J Med Chem; 2007 May; 50(9):2225-39. PubMed ID: 17428043
[TBL] [Abstract][Full Text] [Related]
13. 1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position.
Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH
Bioorg Med Chem Lett; 2009 Mar; 19(6):1807-10. PubMed ID: 19217284
[TBL] [Abstract][Full Text] [Related]
14. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore.
Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH
Bioorg Med Chem Lett; 2009 Mar; 19(6):1802-6. PubMed ID: 19217781
[TBL] [Abstract][Full Text] [Related]
15. 6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors.
Nagasawa JY; Song J; Chen H; Kim HW; Blazel J; Ouk S; Groschel B; Borges V; Ong V; Yeh LT; Girardet JL; Vernier JM; Raney AK; Pinkerton AB
Bioorg Med Chem Lett; 2011 Jan; 21(2):760-3. PubMed ID: 21185178
[TBL] [Abstract][Full Text] [Related]
16. A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors.
Guare JP; Wai JS; Gomez RP; Anthony NJ; Jolly SM; Cortes AR; Vacca JP; Felock PJ; Stillmock KA; Schleif WA; Moyer G; Gabryelski LJ; Jin L; Chen IW; Hazuda DJ; Young SD
Bioorg Med Chem Lett; 2006 Jun; 16(11):2900-4. PubMed ID: 16554152
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors.
Muraglia E; Kinzel O; Gardelli C; Crescenzi B; Donghi M; Ferrara M; Nizi E; Orvieto F; Pescatore G; Laufer R; Gonzalez-Paz O; Di Marco A; Fiore F; Monteagudo E; Fonsi M; Felock PJ; Rowley M; Summa V
J Med Chem; 2008 Feb; 51(4):861-74. PubMed ID: 18217703
[TBL] [Abstract][Full Text] [Related]
18. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties.
Zeng LF; Wang Y; Kazemi R; Xu S; Xu ZL; Sanchez TW; Yang LM; Debnath B; Odde S; Xie H; Zheng YT; Ding J; Neamati N; Long YQ
J Med Chem; 2012 Nov; 55(22):9492-509. PubMed ID: 23098137
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring.
Metobo SE; Jin H; Tsiang M; Kim CU
Bioorg Med Chem Lett; 2006 Aug; 16(15):3985-8. PubMed ID: 16723226
[TBL] [Abstract][Full Text] [Related]
20. Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors.
Ferrara M; Fiore F; Summa V; Gardelli C
Bioorg Med Chem Lett; 2010 Sep; 20(17):5031-4. PubMed ID: 20674351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
